Screener
Phathom Pharmaceuticals, Inc. PHAT Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | $74,274 | $39,503 | $132,575 | $68,023 |
| Cost of revenue | 15,096 | 5,038 | 27,091 | 8,762 |
| Gross profit | 59,178 | 34,465 | 105,484 | 59,261 |
| Operating expenses: | ||||
| Research and development | 7,813 | 9,076 | 15,585 | 18,260 |
| Selling, general and administrative | 55,330 | 85,313 | 109,341 | 179,787 |
| Total operating expenses | 63,143 | 94,389 | 124,926 | 198,047 |
| Loss from operations | (3,965) | (59,924) | (19,442) | (138,786) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s business segments — revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) reported business segments — revenue of $74.27M in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s business segments — revenue changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s business segments — revenue increased by 88.0% year-over-year, from $39.5M to $74.27M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s business segments — revenue?
- Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s business segments — revenue has grown at a 1502.4% compound annual growth rate (CAGR), from $682K to $175.11M.
- What does business segments — revenue mean?
- This represents the total gross income generated from the sale of pharmaceutical products within the company's primary operating segment. It serves as a key indicator of market adoption and commercial success for the firm's therapeutic portfolio. Growth in this metric reflects the effective scaling of product distribution and patient access.
Ask your AI about Phathom Pharmaceuticals, Inc.'s business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude